S M Lippman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Elise D Cook
    Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M D Anderson Cancer Center, Houston 77230 1439, USA
    Clin Trials 2:436-42. 2005
  2. ncbi Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)
    Farshid Dayyani
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Head Neck Oncol 2:15. 2010
  3. ncbi Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture
    Scott M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 66:2893-903. 2006
  4. ncbi The convergent development of molecular-targeted drugs for cancer treatment and prevention
    Scott M Lippman
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:4035-41. 2007
  5. ncbi Fenretinide activity in retinoid-resistant oral leukoplakia
    Scott M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 12:3109-14. 2006
  6. ncbi Cancer prevention science and practice
    Scott M Lippman
    Department of Clinical Cancer Prevention, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 62:5119-25. 2002
  7. ncbi Lung cancer chemoprevention: an integrated approach
    S M Lippman
    Departments of Clinical Cancer Prevention, Thoracic Head and Neck Medical Oncology, and Epidemiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:74S-82S. 2001
  8. ncbi Cancer prevention: from 1727 to milestones of the past 100 years
    Scott M Lippman
    Department of Thoracic Head and Neck Medical Oncology, Unit 432, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Res 69:5269-84. 2009
  9. ncbi Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Scott M Lippman
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    JAMA 301:39-51. 2009
  10. ncbi Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
    S M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 236, Houston, TX 77030 4095, USA
    J Natl Cancer Inst 93:605-18. 2001

Research Grants

  1. U10 Ful Member Application Affiliated with SWOG
    Scott Lippman; Fiscal Year: 2007
  2. Biology of the Prostate Cancer Prevention Trial (PCPT)
    Scott Lippman; Fiscal Year: 2007
  3. MD Anderson Cancer Center SPORE in Head and Neck Cancer
    Scott Lippman; Fiscal Year: 2007

Collaborators

Detail Information

Publications123 found, 100 shown here

  1. ncbi Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Elise D Cook
    Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M D Anderson Cancer Center, Houston 77230 1439, USA
    Clin Trials 2:436-42. 2005
    ..The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer...
  2. ncbi Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)
    Farshid Dayyani
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Head Neck Oncol 2:15. 2010
    ..HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC...
  3. ncbi Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture
    Scott M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 66:2893-903. 2006
    ....
  4. ncbi The convergent development of molecular-targeted drugs for cancer treatment and prevention
    Scott M Lippman
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:4035-41. 2007
    ..These several advances are creating a convergence of cancer therapy with cancer prevention that promises to streamline the development of targeted drugs and improve the control of major cancers...
  5. ncbi Fenretinide activity in retinoid-resistant oral leukoplakia
    Scott M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 12:3109-14. 2006
    ....
  6. ncbi Cancer prevention science and practice
    Scott M Lippman
    Department of Clinical Cancer Prevention, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 62:5119-25. 2002
  7. ncbi Lung cancer chemoprevention: an integrated approach
    S M Lippman
    Departments of Clinical Cancer Prevention, Thoracic Head and Neck Medical Oncology, and Epidemiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 19:74S-82S. 2001
    ....
  8. ncbi Cancer prevention: from 1727 to milestones of the past 100 years
    Scott M Lippman
    Department of Thoracic Head and Neck Medical Oncology, Unit 432, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Res 69:5269-84. 2009
    ..This history of pioneering events may help in better understanding who we are and what we want to achieve as cancer prevention researchers and practitioners...
  9. ncbi Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Scott M Lippman
    Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    JAMA 301:39-51. 2009
    ..Secondary analyses of 2 randomized controlled trials and supportive epidemiologic and preclinical data indicated the potential of selenium and vitamin E for preventing prostate cancer...
  10. ncbi Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer
    S M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 236, Houston, TX 77030 4095, USA
    J Natl Cancer Inst 93:605-18. 2001
    ..Promising data have suggested that retinoid chemoprevention may help to control second primary tumors (SPTs), recurrence, and mortality of stage I non-small-cell lung cancer (NSCLC) patients...
  11. ncbi Oral cancer prevention and the evolution of molecular-targeted drug development
    Scott M Lippman
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:346-56. 2005
    ..New approaches, such as interventions with molecular-targeted agents and agent combinations in molecularly defined high-risk oral IEN patients, are urgently needed to reduce the devastating worldwide consequences of oral cancer...
  12. ncbi Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Scott M Lippman
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 97:94-102. 2005
    ....
  13. ncbi Predicting cancer development in oral leukoplakia: ten years of translational research
    J J Lee
    Department of Biostatistics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Clin Cancer Res 6:1702-10. 2000
    ..This result will need to be validated by future studies. With the identification of high risk individuals, more efficient chemoprevention trials and molecular targeting studies can be designed...
  14. ncbi Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms
    S Y Sun
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 59:2493-8. 1999
    ....
  15. ncbi Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin
    J L Clifford
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Epidemiol Biomarkers Prev 9:993-7. 2000
    ..These data have led to the hypothesis that the loss of IFN sensitivity may contribute to the development and progression of skin SCC...
  16. ncbi Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines
    X C Xu
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 59:2477-83. 1999
    ..These data suggest that the expression of RAR-beta is associated with response of HEC cells to RA and that the loss of RAR-beta expression may be associated with HEC development...
  17. ncbi Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer
    J L Clifford
    Department of Clinical Cancer Prevention The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:391-5. 2001
    ..These in vitro findings warrant further study of these novel phenylretinamides, which may have potential as preventive or therapeutic agents in transitional cell cancer...
  18. ncbi The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial
    F R Khuri
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:823-9. 2001
    ..The results indicate significantly higher SPT rates in active smokers versus never smokers and significantly higher smoking-related SPT rates in active smokers versus never smokers, with intermediate rates for former smokers...
  19. ncbi Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer
    F R Khuri
    Departments of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 18:2798-804. 2000
    ..RAR-beta may suppress tumorigenicity. Therefore, we hypothesized that loss of expression of RAR-beta gene in stage I NSCLC is a prognostic factor of a poor clinical outcome...
  20. ncbi Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer
    Dimitra Tsavachidou
    Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Cancer Inst 101:306-20. 2009
    ....
  21. ncbi Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer
    F R Khuri
    Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 7:861-7. 2001
    ..Future studies of RAR-beta and COX-2 regulation in NSCLC should further the development of prevention and therapy interventions with retinoids and/or COX-2 antagonists in this patient population...
  22. ncbi Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells
    V Subbarayan
    Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer Res 61:2720-6. 2001
    ..Although it is low in stromal and tumor cells, COX-2 expression is induced by TNF-alpha in these cells, and this responsiveness may play an important role in prostate cancer progression...
  23. ncbi Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma
    D M Shin
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 91:1316-23. 2001
    ..The trial hypothesis was that the TIC therapeutic index would be as high as that of paclitaxel, ifosfamide, and cisplatin (TIP) in this setting, but with less toxicity...
  24. ncbi Biochemoprevention for dysplastic lesions of the upper aerodigestive tract
    V A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Arch Otolaryngol Head Neck Surg 125:1083-9. 1999
    ....
  25. ncbi Chromosome polysomy and histological characteristics in oral premalignant lesions
    J Kim
    Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:319-25. 2001
    ....
  26. ncbi p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis
    D M Shin
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:603-9. 2001
    ....
  27. ncbi DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia
    Pierre Saintigny
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:6284-91. 2009
    ..DeltaNp63 is an early oncoprotein associated with mucosal tumorigenesis. The purpose of this study was to assess DeltaNp63 expression in OPL and its role as a marker of oral cancer risk...
  28. ncbi Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia
    Vemparala Subbarayan
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 7:280-93. 2005
    ..These results suggest that feedback mechanisms may contribute to the loss of 15-LOX-2 pathway components, which coincide with an increase in PPAR-gamma in many epithelial cancers...
  29. ncbi Design considerations for efficient prostate cancer chemoprevention trials
    J J Lee
    Departments of Biostatistics The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 57:205-12. 2001
    ....
  30. ncbi Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells
    S Y Sun
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:595-601. 2001
    ..Our results suggest that 2CPR acts via retinoic acid receptors and may be a good candidate for prevention and treatment of some head and neck and lung cancers...
  31. ncbi Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis
    Emile M Youssef
    Departments of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77345, USA
    Clin Cancer Res 10:1733-42. 2004
    ..This study was conducted to determine whether RAR-beta(2) gene expression in such lesions can be silenced by promoter methylation...
  32. ncbi Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells
    Ming Li
    Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, TX 77030, USA
    Oncogene 21:411-8. 2002
    ..Our data demonstrated that anticancer effect of RAR-beta may be related to its ability to suppress COX-2 expression and support that the loss of RAR-beta expression may contribute to esophageal carcinogenesis...
  33. ncbi The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells
    Linda C Hsi
    Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Unit 1360, P.O. Box 301439, Houston, Texas 77230-1439, USA
    Mol Cancer Ther 4:1740-6. 2005
    ..This result has important implications for the study of 5-Azadc and other MTIs in the prevention and therapy of colorectal cancer and supports future investigations of the mechanisms by which MTIs up-regulate 15-LOX-1...
  34. ncbi Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial
    D M Shin
    Departments of Thoracic Head and Neck Medical Oncology, Diagnostic Imaging, Head and Neck Surgery, Biostatistics, Radiation Oncology, and Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 19:3010-7. 2001
    ..We designed the present phase II adjuvant trial to prevent recurrence or second primary tumors (SPTs) using 13-cRA, IFN-alpha, and alpha-tocopherol in locally advanced-stage head and neck cancer...
  35. ncbi Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses
    A S Garden
    Departments of Radiation Oncology, Thoracic Head and Neck Medical Oncology, and Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 17:2390-5. 1999
    ....
  36. ncbi Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer
    Lin Wang
    Departments of Experimental Therapeutics L W, R Z L, J Y, Z L, A N, R C B, Y Y, Clinical Cancer Prevention A H, S M L, and Pathology J L, A A S, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030
    Clin Cancer Res 9:3660-6. 2003
    ..This study investigated the relationship of ARHI expression to the progression of breast cancer...
  37. ncbi Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
    G L Clayman
    Department of Head and Neck Surgery, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2221-32. 1998
    ..Our purpose was to ascertain the safety and therapeutic potential of adenoviral (Ad)-p53 in advanced HNSCC...
  38. ncbi Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention
    Ashraful Hoque
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Carcinogenesis 26:785-91. 2005
    ....
  39. ncbi Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features
    Mahitosh Mandal
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2088-100. 2008
    ..In the current study, the expressions of several factors associated with the induction of EMT in HNSC cell lines and tumor specimens were investigated to define their functional and pathologic role in HNSC...
  40. ncbi Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis
    X C Xu
    Department of Tumor Biology and Epidemiology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Epidemiol Biomarkers Prev 4:871-6. 1995
    ..Thus, CK19 and CK8 could be markers of sequential premalignant changes in head and neck carcinogenesis...
  41. ncbi Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers
    F R Khuri
    The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:311-8. 2001
    ..The modulation of PCNA by 13-cRA in patients who quit smoking suggests a potentially important role for regulating this proliferation marker in retinoid chemoprevention studies of former smokers...
  42. ncbi Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression
    I Shureiqi
    Department of Clinical Cancer, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 61:4879-84. 2001
    ..They also support the concept that the loss of the proapoptotic role of 15-LOX-1 in epithelial cancers is not limited to human colorectal cancers...
  43. ncbi Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    A Hoque
    Department of Clinical Cancer Prevention, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer Causes Control 12:627-33. 2001
    ..CONCLUSION: SELECT offers an excellent opportunity to conduct molecular epidemiologic investigations to assess gene-environment interactions and their role in prostate, lung, and colon carcinogenesis...
  44. ncbi Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei
    Thomas R Salas
    Departments of Clinical Cancer Prevention and Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 278:41338-46. 2003
    ....
  45. ncbi Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions
    Yuanqing Ye
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2488-95. 2008
    ..Cell-cycle checkpoint controls regulate cell-cycle progression and proliferation. Alterations in cell-cycle control mechanisms are linked to tumorigenesis...
  46. ncbi Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice
    Jörg J Jacoby
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    J Thorac Oncol 5:940-9. 2010
    ..To determine the effectiveness of PX-478 against lung tumors, we investigated HIF-1alpha expression in several lung cancer cell lines, both in vitro and in vivo, and treated orthotopic mouse models of human lung cancer with PX-478...
  47. ncbi Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions
    Maosheng Huang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 27:2034-7. 2006
    ..Deregulation of cell cycle plays an important role in tumorigenesis. Cyclin D1 gene (CCND1) is a key regulator of the G(1) phase of the cell cycle...
  48. ncbi Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast
    Ashraful Hoque
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 12:1518-22. 2003
    ..Our data demonstrate that STK15 overexpression correlates with centrosome anomaly and aneuploidy in DCIS, and loss of STK15 overexpression is associated with progression of in situ to ductal invasive breast carcinoma...
  49. ncbi Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast
    A Hoque
    Department of Clinical Cancer Prevention, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA
    Cancer Epidemiol Biomarkers Prev 10:249-59. 2001
    ....
  50. ncbi Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants
    Xifeng Wu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:617-24. 2009
    ..Furthermore, this study underscores the importance of incorporating germ-line genetic variation data with clinical and risk factor data in constructing prediction models for clinical outcomes...
  51. ncbi Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer
    Dong M Shin
    Department of Thoracic/Head and Neck Medical Oncology, Diagnostic Imaging, Biostatistics, Head and Neck Surgery, and Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA
    J Clin Oncol 20:364-70. 2002
    ..Combined 13cRA, IFNalpha, and cisplatin was clinically active in extensive locally advanced disease. Each agent had independent, non-cross-resistant biologic effects in vitro, which may account for the combination's clinical activity...
  52. ncbi Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:2401-8. 2010
    ....
  53. ncbi COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer
    Anita L Sabichi
    Department of Clinical Cancer Prevention, University of Texas M.D. Amderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Semin Oncol 31:36-44. 2004
    ..Future studies likely will focus on clarifying the NSAID mechanisms behind and developing NSAID combinations for both treating and preventing GU cancers...
  54. ncbi Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma
    Abenaa M Brewster
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:1974-8. 2007
    ....
  55. ncbi Nucleotide excision repair pathway genes and oral premalignant lesions
    Yunfei Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:3753-8. 2007
    ..Polymorphisms in NER genes may cause variations in DNA repair capacity and increase susceptibility to both premalignant lesions and cancer...
  56. ncbi Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy
    Hidetoshi Kawaguchi
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:354-60. 2008
    ..The purpose of this study is to determine a role of podoplanin in predicting oral cancer development in patients with OPL...
  57. ncbi The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival
    W N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 23:78-85. 2012
    ..The aim of this study is to investigate the prognostic role of phosphorylated AMP-activated protein kinase (pAMPK) in surgically resected non-small-cell lung cancer (NSCLC)...
  58. ncbi p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas
    A K El-Naggar
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 22:729-35. 2001
    ....
  59. ncbi The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease
    G L Clayman
    Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Campus Box 441, Houston, TX 77030, USA
    Arch Otolaryngol Head Neck Surg 127:135-9. 2001
    ..To analyze and compare the effectiveness of sequential platinum-based chemotherapy and radiotherapy with and without selective neck dissection in patients with N2a and greater stage node-positive squamous cell carcinoma of the oropharynx...
  60. ncbi Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Clin Oncol 33:148-52. 2010
    ..The aim of this phase 2 study was to investigate the use of docetaxel and vinorelbine in the frontline and second-line setting in patients with incurable non-small-cell lung cancer...
  61. ncbi 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation
    Xiangsheng Zuo
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    FASEB J 22:1981-92. 2008
    ..DNMT-1 has a direct suppressive role in 15-LOX-1 transcriptional silencing that is independent of 15-LOX-1 promoter DNA methylation...
  62. ncbi Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity
    Thomas R Salas
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 279:19191-200. 2004
    ....
  63. ncbi Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck
    Dong M Shin
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 95:322-30. 2002
    ..We also hypothesized that improved complete response (CR) rates with the induction chemotherapy may render better survival rates with subsequently delivered definitive local treatment...
  64. ncbi RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoA
    Zheng D Liang
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 66:7111-8. 2006
    ..Our findings therefore show a novel molecular pathway involving RAR-beta2 regulation of RRIG1 expression and RRIG1-RhoA interaction. An understanding of this pathway may translate into better control of human cancer...
  65. ncbi Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis
    X C Xu
    Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Cancer Res 61:4306-10. 2001
    ..Our results indicate that suppressed expression of retinoid receptors occurs early (in AK) and is associated with progression of squamous skin carcinogenesis to SCC...
  66. ncbi Lipoxygenase modulation to reverse carcinogenesis
    I Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 61:6307-12. 2001
    ..e., agents that can induce the anticarcinogenic and/or inhibit the procarcinogenic LOXs, thereby shifting the balance of LOX activities from procarcinogenic to anticarcinogenic metabolism of polyunsaturated fatty acids...
  67. ncbi Cloning and characterization of the human retinoid X receptor alpha gene: conservation of structure with the mouse homolog
    G Li
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biochem Biophys Res Commun 269:54-7. 2000
    ..These results provide information necessary to generate constructs for targeting the RXRalpha gene in human cell lines, which may eventually lead to an understanding of the function of RXRalpha in human cancer...
  68. ncbi 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma
    V Subbarayan
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 25:6015-25. 2006
    ..These data suggest that crosstalk mechanisms exist between the 15-LOX-2 gene and PPARgamma to counterbalance expression and help explain the inverse relationship of these genes in normal versus cancer cells...
  69. ncbi Computerized image analysis of Ki-67 in ductal breast carcinoma in situ
    D G Menter
    Departments of Clinical Cancer Prevention and Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Anal Quant Cytol Histol 23:218-28. 2001
    ..As such, this method can offer (1) less intraobserver and interobserver variability, (2) a digital archival record, and (3) a baseline for digital exchange of information between studies...
  70. ncbi Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer
    M Duvic
    Department of Internal Medical Specialties, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 6:3249-59. 2000
    ..012). TIG-3 mRNA was significantly higher in normal control skin (P = 0.001), in paired adjacent skin (median, 3; P = 0.007), and in overlying epidermis (median, 3.0; P = 0.0001) than in 21 SCC specimens as a group (median, 1.5)...
  71. ncbi GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells
    Imad Shureiqi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 62:1178-83. 2002
    ..Ectopic GATA-6 expression blocked NSAID induction of 15-LOX-1 and apoptosis. NSAIDs down-regulate GATA-6 to transcriptionally up-regulate 15-LOX-1 and induce apoptosis in colorectal cancer cells...
  72. ncbi Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Clin Cancer Res 14:224-9. 2008
    ..The study aims to evaluate the efficacy and toxicity of fenretinide in preventing tumor recurrence in patients with transitional cell carcinoma (TCC) of the bladder...
  73. ncbi Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression
    Li E Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:6532-9. 2007
    ..To examine the role of suboptimal DNA repair capacity (DRC) for UV light-induced DNA damage in the development of nonmelanoma skin cancer (NMSC) and tumor progression...
  74. ncbi Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions
    Xia Pu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1498-506. 2009
    ..Single-nucleotide polymorphisms of COX-2 have been associated with the risk of multiple cancers; however, to date, their effects on OPL susceptibility have not been evaluated sufficiently...
  75. ncbi Pilot randomized phase II study of celecoxib in oral premalignant lesions
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2095-101. 2008
    ..In this pilot randomized phase II study, we evaluated the efficacy and safety of the COX-2 inhibitor celecoxib in patients with oral premalignant lesions (OPL)...
  76. ncbi Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002
    Scott M Lippman
    Department of Clinical Cancer Prevention, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 8:305-13. 2002
  77. ncbi Phase II study of dasatinib in patients with advanced non-small-cell lung cancer
    Faye M Johnson
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:4609-15. 2010
    ..We tested the hypotheses that the activation of epidermal growth factor receptor (EGFR) or SFK or modulation of serum cytokines may predict a response to dasatinib...
  78. ncbi Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma
    Jianming Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 31:1755-61. 2010
    ..Our results stressed the importance of taking a polygenic approach to evaluate the cumulative and interaction effects of genetic variations in the prediction of cancer risk and prognosis...
  79. ncbi Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer
    Lauren Averett Byers
    Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:1755-63. 2010
    ..In conclusion, serum CAF profiling, particularly in HPV-negative patients, may be useful for identifying those at highest risk for recurrence...
  80. ncbi Prospective imaging assessment of mortality risk after head-and-neck radiotherapy
    Benjamin J Moeller
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 78:667-74. 2010
    ..Unresolved questions include whether functional or anatomic imaging might improve mortality risk assessment for this disease. We addressed these issues in a prospective institutional trial...
  81. ncbi Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, Unit 432, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 8:521-32. 2009
    ..These results suggest that when guided by MACS, screening larger drug combinations may be feasible as a first step in combination drug discovery in a relatively small number of experiments...
  82. ncbi High-dose fenretinide in oral leukoplakia
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:22-6. 2009
    ..This result is consistent with our clinical finding that high-dose fenretinide did not improve on the historical response rate of lower-dose fenretinide in our previous oral leukoplakia trial...
  83. ncbi Cyclin D1 and cancer development in laryngeal premalignancy patients
    Vassiliki Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 2:14-21. 2009
    ..04) and within each CD1 genotype group. These findings support CD1 genotype and protein expression as important risk markers for laryngeal cancer and suggest future trials targeting upstream regulators of CD1 transcription...
  84. ncbi Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy
    Vassiliki A Papadimitrakopoulou
    Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:599-604. 2009
    ....
  85. ncbi Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study
    Anita L Sabichi
    University of Texas M D Anderson Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 12:2178-84. 2006
    ..Epidemiologic and clinical data suggest that selenium could prevent prostate cancer, but it has not been shown that supplemental selenium leads to an increased concentration of selenium in prostate tissue compared with adjacent tissue...
  86. ncbi Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ
    Jinsong Liu
    Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Oncol 24:879-84. 2004
    ....
  87. ncbi Mortality risk from squamous cell skin cancer
    Gary L Clayman
    Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:759-65. 2005
    ..To identify nonmelanoma skin cancer patients with squamous cell carcinoma (SCC) who are at greatest risk of disease-specific mortality...
  88. ncbi COX-2 inhibitors and other NSAIDs in bladder and prostate cancer
    Anita L Sabichi
    Department of Clinical Cancer Prevention, University of Texas M.D. Anderson Cancer Center, Houston, Tex, USA
    Prog Exp Tumor Res 37:163-78. 2003
  89. ncbi The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells
    Imad Shureiqi
    Departments of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 100:9968-73. 2003
    ..Our findings indicate that the down-regulation of PPAR-delta by 15-LOX-1 through 13-S-HODE is an apoptotic signaling pathway that is activated by NSAIDs...
  90. ncbi Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma
    Xiao Chun Xu
    Department of Clinical Cancer Prevention, Unit 1360, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 14:826-9. 2005
    ..These are the first in vivo expression patterns of RAR-beta2 and RAR-beta4 reported in humans or animals and support the in vitro data on these isoforms and their contrasting biological effects in human carcinogenesis...
  91. ncbi The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells
    Linda C Hsi
    Department of Clinical Cancer Prevention, Gastrointestinal Medical Oncology, and Division of Cancer Prevention, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 64:8778-81. 2004
    ....
  92. ncbi Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial
    Merrill S Kies
    Departments of Thoracic Head and Neck Medical Oncology, Head and Neck Surgery, Radiation Oncology, Biostatistics, Radiology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:8-14. 2010
    ..PFS is promising, and this sequential treatment strategy should be further investigated. Patients with HPV-positive tumors have an excellent prognosis...
  93. ncbi Identification of benzo(a)pyrene diol epoxide-binding DNA fragments using DNA immunoprecipitation technique
    Zhengdong Liang
    Department of Clinical Cancer Prevention, University of Texas M D Anderson Cancer Center, Houston Texas 77030, USA
    Cancer Res 63:1470-4. 2003
    ..These data further demonstrate that BPDE-induced gene alterations are important events in carcinogenesis and that the identification of the resulting clones may help us to better understand the mechanisms of BPDE-induced carcinogenesis...
  94. ncbi Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells
    Anita L Sabichi
    Department of Clinical Cancer Prevention, Unit 236, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 13:1704-9. 2004
    ..The present study showed that PPAR-gamma activation can be an important regulator of COX-2 in prostate cells and may be an important target for prostate cancer chemoprevention...
  95. ncbi The convergence of cancer prevention and therapy in early-phase clinical drug development
    James L Abbruzzese
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:321-6. 2004
    ..The future full convergence of prevention-therapy drug development (aided by technological advances, such as in molecular imaging) promises to hasten the progress of oncology in reducing the public health impact of the major cancers...
  96. ncbi Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398
    Xiao Chun Xu
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Neoplasia 5:121-7. 2003
    ..Further investigation of the effects of nonsteroidal anti-inflammatory drugs on 15-LOX-2 expression and apoptosis in esophageal cancer cells may be warranted...
  97. ncbi Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy
    I Shureiqi
    The University of Texas M D Anderson Cancer Center, Department of Clinical Cancer Prevention, 1515 Holcombe Boulevard, Box 236, Houston, TX 77030, USA
    Br J Cancer 86:226-32. 2002
    ..The use of multiple gated acquisition scans for pretreatment screening appears to be more cost-effective for patients who are 40 years or older, when cumulative doxorubicin dose is 350 mg m(-2) or less...
  98. ncbi Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity
    X Zuo
    Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA
    Oncogene 25:1225-41. 2006
    ..These findings elucidate a novel mechanism of the signaling by natural ligands of PPARs, which involves modulating the interaction between PPAR-b/d and PPAR-g...
  99. ncbi Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells
    J L Clifford
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 59:14-8. 1999
    ..Therefore, two distinct effects of 4HPR were identified in this system: a rapid induction of cell death and a slower induction of differentiation, which are likely to be receptor independent and dependent, respectively...
  100. ncbi Can selenium prevent colorectal cancer? A signpost from epidemiology
    Anna J Duffield-Lillico
    J Natl Cancer Inst 96:1645-7. 2004
  101. ncbi Science peels the onion of selenium effects on prostate carcinogenesis
    Philip R Taylor
    J Natl Cancer Inst 96:645-7. 2004

Research Grants7

  1. U10 Ful Member Application Affiliated with SWOG
    Scott Lippman; Fiscal Year: 2007
    ..abstract_text> ..
  2. Biology of the Prostate Cancer Prevention Trial (PCPT)
    Scott Lippman; Fiscal Year: 2007
    ....
  3. MD Anderson Cancer Center SPORE in Head and Neck Cancer
    Scott Lippman; Fiscal Year: 2007
    ..We will bring all of our resources to bear on this problem. ..